JP2010505897A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505897A5
JP2010505897A5 JP2009531778A JP2009531778A JP2010505897A5 JP 2010505897 A5 JP2010505897 A5 JP 2010505897A5 JP 2009531778 A JP2009531778 A JP 2009531778A JP 2009531778 A JP2009531778 A JP 2009531778A JP 2010505897 A5 JP2010505897 A5 JP 2010505897A5
Authority
JP
Japan
Prior art keywords
kinase
influenza virus
gene
pharmaceutical composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009531778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/008852 external-priority patent/WO2008043561A2/en
Publication of JP2010505897A publication Critical patent/JP2010505897A/ja
Publication of JP2010505897A5 publication Critical patent/JP2010505897A5/ja
Pending legal-status Critical Current

Links

JP2009531778A 2006-10-11 2007-10-11 インフルエンザターゲット Pending JP2010505897A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85065106P 2006-10-11 2006-10-11
PCT/EP2007/008852 WO2008043561A2 (en) 2006-10-11 2007-10-11 Influenza targets

Publications (2)

Publication Number Publication Date
JP2010505897A JP2010505897A (ja) 2010-02-25
JP2010505897A5 true JP2010505897A5 (cg-RX-API-DMAC7.html) 2010-10-21

Family

ID=39203225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531778A Pending JP2010505897A (ja) 2006-10-11 2007-10-11 インフルエンザターゲット

Country Status (7)

Country Link
US (1) US20110150897A1 (cg-RX-API-DMAC7.html)
EP (1) EP2087110A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010505897A (cg-RX-API-DMAC7.html)
AU (1) AU2007306542B2 (cg-RX-API-DMAC7.html)
CA (1) CA2666185A1 (cg-RX-API-DMAC7.html)
SG (1) SG166778A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008043561A2 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EA200900741A1 (ru) 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2276455A2 (fr) * 2008-04-22 2011-01-26 Centre National de la Recherche Scientifique Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2405921A4 (en) * 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
WO2010111468A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
CN102459595A (zh) 2009-04-24 2012-05-16 普罗森那技术公司 用于治疗dmd的包含肌苷的寡核苷酸
WO2011071535A2 (en) * 2009-12-11 2011-06-16 Mount Sinai School Of Medicine Of New York University Compositions and methods for inhibiting human host cell factors required for influenza virus replication
JP2013515697A (ja) * 2009-12-23 2013-05-09 マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ インフルエンザ標的
EP2563921B1 (en) * 2010-04-30 2016-11-23 Cellectis Method for modulating double-strand break-induced homologous recombination
CN109112126B (zh) * 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
EP2633052B1 (en) * 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
EP2446883A1 (en) * 2010-10-30 2012-05-02 University College Cork-National University of Ireland, Cork Treatment of inflammation
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
WO2012122645A1 (en) * 2011-03-11 2012-09-20 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
US20140227289A1 (en) * 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013157215A1 (ja) * 2012-04-17 2013-10-24 国立大学法人山口大学 子宮体がん発症感受性の判定方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
BR112015022156A2 (pt) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
EP2853596A1 (en) 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Protein phosphatase inhibitor
US20160333346A1 (en) 2014-01-17 2016-11-17 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of inhibiting expression of beta-2gpi
JP6663149B2 (ja) * 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US20190071668A1 (en) * 2015-07-08 2019-03-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms
CA3005131A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of tuberous sclerosis complex
PT109454A (pt) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
MD3519572T2 (ro) 2016-09-29 2024-03-31 Biogen Ma Inc Compuși și procedee de reducere a expresiei Tau
TW201903149A (zh) 2017-05-31 2019-01-16 日商協和醱酵麒麟有限公司 抑制apcs之表現的核酸
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
CN111212909A (zh) * 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
EP3710587A1 (en) * 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
MY207352A (en) * 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
EP3689896A1 (en) * 2019-01-31 2020-08-05 Universität Heidelberg Grk2 modulating mirnas
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス,エルエルシー MRGX2の阻害薬である3-アミノ-4H-ベンゾ[e][1,2,4]チアジアジン1,1-ジオキシド誘導体
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
CN115397989A (zh) 2020-02-18 2022-11-25 阿尔尼拉姆医药品有限公司 载脂蛋白C3(APOC3)iRNA组合物及其使用方法
US20230190785A1 (en) * 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
WO2022072356A1 (en) * 2020-09-29 2022-04-07 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
CA3200595A1 (en) * 2020-11-13 2022-05-19 Alnylam Pharmaceuticals, Inc. Coagulation factor v (f5) irna compositions and methods of use thereof
GB202411150D0 (en) * 2024-07-30 2024-09-11 Res & Innovation Uk Therapeutic antisense oligomers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
US20030219895A1 (en) * 2002-05-22 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of CDC-like kinase 1 expression
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
DE10313636A1 (de) * 2003-03-26 2004-10-14 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen

Similar Documents

Publication Publication Date Title
Keshavarz et al. Influenza vaccine: Where are we and where do we go?
Melchjorsen et al. Activation and evasion of innate antiviral immunity by herpes simplex virus
AU2007306542B2 (en) Influenza targets
Diehl et al. Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway
Wang et al. Epigenetic changes in the regulation of Nicotiana tabacum response to cucumber mosaic virus infection and symptom recovery through single-base resolution methylomes
Abbott et al. Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza
Dhungel et al. Vaccinia virus as a master of host shutoff induction: targeting processes of the central dogma and beyond
JP2006525796A5 (cg-RX-API-DMAC7.html)
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
Falcone et al. The small RNA ErsA of Pseudomonas aeruginosa contributes to biofilm development and motility through post-transcriptional modulation of AmrZ
Elliott et al. Bunyaviruses and the type I interferon system
Ellison et al. Control of VP16 translation by the herpes simplex virus type 1 immediate-early protein ICP27
Olivier et al. Innate immunity activation and RNAi interplay in citrus exocortis viroid—Tomato pathosystem
Shmaryahu et al. Prediction of bacterial microRNAs and possible targets in human cell transcriptome
Bourhill et al. Going (reo) viral: Factors promoting successful reoviral oncolytic infection
Qiao et al. The role of plant DNA methylation in development, stress response, and crop breeding
Tucker et al. Alteration of the premature tRNA landscape by gammaherpesvirus infection
Koczka et al. Comparative transcriptome analysis of a Trichoplusia ni cell line reveals distinct host responses to intracellular and secreted protein products expressed by recombinant baculoviruses
Deng et al. The role of latency-associated transcripts in the latent infection of pseudorabies virus
Brown et al. Immunopathogenesis of Nipah virus infection and associated immune responses
Lu et al. The multifaceted interactions between Newcastle disease virus proteins and host proteins: a systematic review
Venios et al. Emerging roles of epigenetics in grapevine and winegrowing
Jang et al. Molecular responses to the influenza A virus in chicken trachea-derived cells
Pandolfo et al. Unmasking pediatric asthma: epigenetic fingerprints and markers of respiratory infections
Wang et al. Strong opponent of walnut anthracnose—Bacillus velezensis and its transcriptome analysis